Pfizer today said its COVID-19 vaccine will receive a priority review from the Food and Drug Administration, indicating that Pfizer has completed its rolling submission of its application for the vaccine’s full authorization. The company’s Biologics License Application, which is intended for individuals age 16 and older, is supported by clinical date from its phase 3 clinical trial.

Related News Articles

Headline
The AHA, America’s Essential Hospitals, Association of American Medical Colleges, Catholic Health Association of the United States, and Children’s Hospital…
Headline
The Centers for Disease Control and Prevention today adjusted its guidance for fully vaccinated individuals, urging indoor masking in states that are labeled…
Headline
The Health Resources and Services Administration today awarded 127 organizations a total of $121 million in American Rescue Plan Act funds to work with…
Headline
The Food and Drug Administration last week issued an emergency use authorization to Becton, Dickinson and Company for its sodium citrate blood specimen…
Headline
The Federal Emergency Management Agency Friday released an advisory on reimbursable communications and outreach expenses for nonprofit medical facilities and…
Headline
Pfizer Inc. today announced that the federal government has agreed to purchase an additional 200 million doses of its COVID-19 vaccine. The deal raises the…